PubRank

Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (PLASCOSSA)

Clinical Trial ID NCT04372979

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04372979

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 18.32
2 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 10.16
3 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
4 Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016 6.22
5 Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004 3.76
6 Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003 3.34
7 The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014 1.88
8 Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011 1.68
9 Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003 1.59
10 Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 1.23
11 Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005 1.00
12 Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004 0.93
13 The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. Clin Infect Dis 2015 0.92
14 Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One 2014 0.84
15 A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005 0.81
16 Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol 2016 0.78
17 Management of disseminated intravascular coagulation: a survey of the International Society on Thrombosis and Haemostasis. Thromb Res 2015 0.75
18 Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 2015 0.75
19 Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol 2017 0.75
20 Loss of Syndecan-1 Abrogates the Pulmonary Protective Phenotype Induced By Plasma After Hemorrhagic Shock. Shock 2017 0.75
21 Early and repeated use of plasma for the management of Ebola patients: Reflection around a case. Transfus Clin Biol 2016 0.75
22 Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog 2017 0.75
Next 100